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Long-term renal effects of unilateral ureteral obstruction and to investigate the alteration to renal function in the early
the role of endothelin. stages (hours) after ureteral obstruction-[2, 3]; however,
Background. Angiotensin II (Ang II) and endothelin (ET) few studies have addressed the longer-term effects ofare involved in the alteration of renal function in unilateral
reversible ureteral obstruction on renal hemodynamicsureteral obstruction (UUO). The renal response to Ang II
or tubular function. Nonetheless, Bander et al measuredfollowing the reversal of a 24-hour UUO and the effect of ET
blockade by bosentan during the time of obstruction were renal function under baseline conditions sequentially for
investigated. up to 60 days following a reversible 24-hour unilateral
Methods. Following blockade of the endogenous production ureteral obstruction (UUO) in the rat [4]. In this model,of Ang II by captopril, the renal response to Ang II was studied
it was shown that renal blood flow (RBF), glomerularin rats 15 to 18 days after a 24-hour UUO (N 5 10) or a sham
filtration rate (GFR), and absolute (UNaV) and fractionaloperation (N 5 9) both with (N 5 10) and without (N 5 8)
bosentan treatment in the periobstruction period. Similar stud- excretion of sodium (FENa) return to normal by 14 days
ies were performed in another group (N 5 9) two months after the reversal of the obstruction. However, the sus-
following the reversal of obstruction.
tained low urine osmolality for up to two months follow-Results. In the sham-operated group, Ang II reduced renal
ing the obstruction reversal was indicative of a persistentblood flow (RBF) by 42 6 9% (P , 0.01), glomerular filtration
rate (GFR) by 30 6 8% (P , 0.01), urine volume (UV) by 44 6 functional defect in the distal nephron.
9% (P , 0.001), and absolute (UNaV) and fractional sodium Endothelins (ETs) are a family of three potent vaso-
excretion (FENa) by 52 6 9% (P , 0.001) and 33 6 9% (P 5 constrictor isopeptides (ET-1, ET-2, and ET-3) [5], for
0.054), respectively. In the previously obstructed kidney, Ang
which at least two types of receptors have been identifiedII did not change RBF but increased GFR by 106 6 40% (P ,
(ETA and ETB) [6]. It has been shown that renal tissue0.01), UV by 75 6 21% (P , 0.001), UNaV by 190 6 60% (P ,
0.001), and FENa by 40 6 13% (P , 0.05). Bosentan treatment can synthesize ET, and it expresses both ETA and ETB
in the obstructed group prevented these Ang II-induced effects receptors [7]. ET plays an important role in several renal
and did not have any effect on the sham-operated kidney. Two pathophysiological conditions [7]. Indeed, complete ob-months following reversal of the obstruction, the response of
struction of one ureter in three-week-old weanling ratsthe kidney was similar to that of the control kidney.
increased ET concentration in renal tissue significantlyConclusion. Twenty-four–hour UUO results in a temporary
abnormality in the renal response to Ang II, which is due, in [8]. Furthermore, prior inhibition of the biological action
part, to the actions of ET at the time of obstruction. of ET-1 by a specific antibody significantly attenuated
the fall in GFR and effective renal plasma flow (ERPF)
in rats after unilateral release of 24-hour bilateral ure-
Ureteral obstruction is a relatively common clinical teral obstruction [9].
problem in humans that can lead to pain and ultimately Bosentan, an orally active mixed ETA/ETB receptor
to renal damage [1, 2]. The renal damage is due to the antagonist, has been shown to have a protective effect
interaction of various factors leading to alterations in in a number of renal pathophysiological conditions, in-
glomerular and tubular function at the time of obstruc- cluding nephritis, renal tissue loss, and rhabdomyolysis-
tion [1–3]. Several animal studies have been performed induced renal failure [10–12]. Therefore, the possibility
exists that it may also have a protective role in the long-
term renal damage caused by ureteral obstruction.Key words: bosentan, angiotensin II, captopril, hemodynamics, vaso-
constriction. Angiotensin II (Ang II) plays an important role in
the control of sodium excretion by the kidneys underReceived for publication July 13, 1999
physiological and pathophysiological conditions [13, 14].and in revised form November 12, 1999
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the postobstructed kidney exhibits an abnormal response istered orally (150 mg/kg/day) in the periobstruction or
to Ang II [18, 19]. In the rabbit, Nishikawa, Morrison, sham procedure periods. Bosentan was given for four
and Needleman demonstrated an increase in the Ang days commencing 24 hours prior to obstruction or sham
II-induced prostaglandin release by the postobstructed procedures and continued for three days after operation.
kidney [18]. Furthermore, the contractile response of The drug was mixed with a small quantity of pulverized
strips of rabbit renal cortex to Ang II is enhanced in the rat chow (5 g) made into loose pellets by adding water
postobstructed kidney [19], indicating an increase in the and then drying it under 378C. The pellets were placed
number and/or affinity of the Ang II receptors under inside the cage each evening, and all other food was re-
these conditions [20]. moved to ensure that the full dose of bosentan was taken.
The aim of this study was thus to investigate the long- The following morning, regular rat chow was made avail-
term in vivo renal response to physiological doses of able. In this way, the animal would rapidly ingest the
Ang II, which affect both hemodynamic and tubular bosentan, resulting in a rapid increase in plasma levels.
functions two weeks and two months following reversal Its long half-life means that the plasma levels remains
of a 24-hour UUO in the rat. Furthermore, the effect of in the therapeutic range throughout the treatment period
an ET blockade at the time of obstruction on the re- [21, 22].
sponse to Ang II was investigated.
Surgical procedure in the terminal experiment
Rats were fasted overnight but had water ad libitum.METHODS
Each animal was anesthetized with pentobarbitone so-
Studies were performed in male Wistar rats weighing dium (60 to 70 mg/kg, intraperitoneally; Nembutal, Vir-
230 to 245 g at the time of ureteral obstruction or sham bac, New Zealand), and the trachea was cannulated.
operation. Animals were supplied by the Department Following cannulation of a femoral vein with polyethyl-
of Laboratory Animals Sciences, University of Otago.
ene tubing (PE-50), anesthesia was maintained by a con-
Animal procedures were approved by University of
tinuous infusion of pentobarbitone sodium (12.5 mg/
Otago Animal Ethics Committee. Rats were kept in a
kg/hour), and a sustaining infusion of 0.9% saline was12-hour light/dark cycle at 208C and fed a standard rat
established at a rate of 50 mL/min using an infusionchow, and the rats had access to water ad libitum.
pump (IITC Life Science, Woodland Hills, CA, USA).
A femoral artery was cannulated, and the tip of theUreteral occlusion/sham operation and reversal
cannula was positioned just below the level of the renalThe following procedures were carried out under aseptic
artery. The cannula was connected to a pressure trans-conditions. Induction of anesthesia was achieved by admin-
ducer (Statham P23AC, Hato Rey, Puerto Rico). Theistering 4% halothane (fluothane, I.C.I.; Zeneca, Maccles-
blood pressure signal was amplified using a MacLabfield, UK), nitrous oxide and oxygen at a rate of 2 and
bridge Amp (ADInstruments, Castle Hill, Australia),3 L/min, respectively. Surgical anesthesia was maintained
digitized using a MacLab/4 and version 3.5.4 softwareby administration of 1.5 to 3.5% fluothane in oxygen at
(ADInstruments) and displayed on a Macintosh LCIIIa rate of 1 L/min. The left kidney and ureter were exposed
computer. The measured pressure was used as an esti-via a flank incision. Using the technique described by
mate of the mean renal arterial pressure (RAP). TheBander et al, the ureter was obstructed by placing a 3
arterial cannula was also used to obtain blood samplesto 4 mm length of bisected PVC tubing (0.58 mm internal
throughout the procedure as required. The left kidneydiameter) around the left midureter [4]. The ureter was
was exposed through a flank incision, and its upper ureterthen occluded by constricting the tubing with a 4-0 silk
was cannulated with polyethylene tubing (PE-10) for thesuture. At the end, the wound was closed in layers.
collection of urine in preweighed microcapped tubes.Twenty-four hours later, all animals underwent rever-
The urine volume (UV) was determined gravimetrically.sal procedures. Using similar anesthesia as described
The renal nerves were visualized and sectioned to elimi-previously in this article, the left kidney and ureter were
nate the effect of renal nerves on kidney function. Theapproached through the same incision. Using a dissecting
renal artery and vein were completely stripped of con-microscope, the obstructing tube was identified and re-
nective tissue and painted with absolute alcohol tomoved. Full release of the obstruction was confirmed by
achieve complete denervation [23, 24]. The right ureterobservation of a free flow of urine across the site of
was cannulated to provide a continuous drainage ofobstruction. The wound was then closed.
urine, thus preventing reno-renal responses caused bySham animals underwent identical surgical proce-
increased right ureteral pressure. A length of thread wasdures, but the left ureter was simply manipulated.
looped around the aorta above the level of renal arteries
Bosentan administration and attached to a screw device. This adjustable constric-
tor was used to control the RAP during Ang II infusion.Bosentan (Ro 47-0203/029; Roche, Zurich, Switzer-
land), a mixed ETA/ETB receptor antagonist, was admin- The thread on the screw device had a fine pitch that
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provided a precise control of blood pressure such that Experimental groups
the mean pressure over the period of Ang II infusion Animals were divided into five groups.
was 62 mm Hg from the desired pressure, that is, the (1) Sham group (N 5 9). These rats underwent manipu-
pressure during captopril infusion only. lation of the left ureter only and acted as a control group.
On completion of the surgery, the sustaining infusion (2) UUO group (N 5 10). These rats underwent left
was replaced by one containing inulin (1.5% weight/ ureteral obstruction.
volume) and para-aminohippuric acid (PAH; 0.2% (3) B/sham group (N 5 8). These rats underwent ma-
weight/volume). A priming dose of 2 mL of the same nipulation of the left ureter and received bosentan treat-
solution was infused over two minutes. Animals were ment.
allowed two hours to equilibrate before being subjected (4) B/UUO group (N 5 10). These rats underwent left
to the experimental protocol. ureteral obstruction and received bosentan treatment.
These four groups had their renal function measured
Experimental protocol and assays 15 to 18 days following reversal of the obstruction.
The experimental protocol consisted of seven 15-min- (5) UUO/LT group (N 5 9). These rats had ureteral
ute clearance periods. Following two baseline clearance obstruction, and the renal function was measured 59
periods, captopril (900 mg/kg/hour; Sigma, St. Louis, to 63 days following reversal of the obstruction. Renal
MO, USA), an angiotensin I-converting enzyme (ACE) function of the postobstructed left kidney was compared
inhibitor, was added to the infusion to block the produc- with the right kidney.
tion of endogenous Ang II. Captopril infusion was con-
tinued thereafter until the end of the protocol. Thirty Statistical analysis
minutes were allowed for the captopril action to take Statistical analysis was performed with the StatView
effect. The effectiveness of captopril was determined by IV system (Abacus Concepts, Inc., Berkeley, CA, USA)
infusing 200 ng of angiotensin I (Sigma) dissolved in 0.2 designed for the Macintosh computer. All data are ex-
mL of normal saline before and 30 minutes after the pressed as mean 6 SEM. Analysis of variance (ANOVA)
start of the captopril infusion. If the pressor response of with repeated measures was used to identify changes in
angiotensin I was reduced to less than 10% of the re- each variable as a consequence of treatment with capto-
sponse prior to captopril, blockade of Ang II production pril and Ang II. Where appropriate, intragroup compari-
was considered to be effective [25]. son between basal and captopril treatment and between
Following two clearance periods in the presence of captopril and Ang II were carried out using a Student’s
captopril, Ang II (acetate salt, 25 ng/kg/min; Sigma) was paired t-test. A comparison between groups was achieved
introduced to the infusion. Fifteen minutes were allowed using one-way factorial ANOVA. A value of P , 0.05
to servo-control the RAP at a pre-angiotensin level and was considered significant.
for the passage of the preformed urine. Once stabilized,
a further 15-minute urine collection was performed. The
RESULTSinfusion of Ang II was then terminated, and two recovery
collections were made. Finally, the animals were euthan- The basal blood pressure and renal function variables
ized with an overdose of barbiturate and the kidneys in the sham, UUO, B/sham, and B/UUO groups were
weighed. similar and are shown in Table 1.
Arterial blood samples (0.4 mL) taken at the beginning
Response of the sham groupand end of the basal, captopril, Ang II and recovery
periods were immediately centrifuged. Plasma samples Captopril administration resulted in a 7 6 1% (P ,
(125 mL) were frozen to be assayed later. The plasma 0.01) decrease in RAP. RBF and GFR increased by 34 6
was replaced by an equal volume of saline, and the eryth- 12% and 34 6 9%, respectively (P , 0.05 in both cases).
rocytes were resuspended by gentle vortexing and were Similarly, urine flow rate (UV), UNaV, and FENa excretion
returned to the animal. The hematocrit was determined. increased by 60 6 20% (P , 0.001), 236 6 86% (P ,
Urine and plasma samples were assayed for sodium 0.001), and 169 6 79% (P , 0.01), respectively (Table 1).
using a flame photometer (SEAC, Florence, Italy). Inulin During the infusion of Ang II, RAP was successfully
and PAH content were determined using modified tech- maintained at a preinfusion level by adjusting the aortic
niques described by Bojesen [26] and Bratton and Mar- constrictor. Ang II reduced RBF and GFR by 42 6 9%
and 30 6 8%, respectively (P , 0.01 in both cases), andshall [27], respectively. GFR was estimated from the
clearances of inulin. RBF was calculated using the for- reduced UV and UNaV by 44 6 9% (P , 0.001) and 52 6
9% (P , 0.001), respectively. FENa decreased by 33 6mula [RBF 5 ERPF/(1 2 hematocrit)], where the clear-
ance of PAH was used as an estimate to ERPF. All renal 9%, but this reduction just failed to reach significance
(P 5 0.054; Figs. 1 and 2).data were corrected for kidney weight.
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Table 1. Blood pressure and renal hemodynamic and tubular data of the left kidney from the sham, unilateral ureteral obstruction (UUO),
B/Sham and bosentan (B)/UUO groups during the basal conditions and with captopril infusion
Sham (N 5 9) UUO (N 5 10) B/Sham (N 5 8) B/UUO (N 5 10)
Basal Captopril Basal Captopril Basal Captopril Basal Captopril
BP mm Hg 9963 9262b 10261 9362c 10363 9464b 10364 9664a
RBF mL/min/g 4.4060.45 6.1460.87a 4.6360.62 4.9960.48 4.8360.66 7.3461.05b 4.9960.59 6.7060.71b
GFR mL/min/g 0.7960.09 1.0160.10a 0.8460.06 0.7160.07 0.7360.14 1.0960.14b 0.7360.09 1.1160.11c
UV lL/min/g 12.5361.87 17.7262.20c 13.5261.60 9.9461.66c 11.7861.93 16.3462.56a 9.7061.84 14.4062.49a
UNaV lmol/min/g 1.3760.34 2.8660.50c 1.3260.27 1.2160.33 1.4760.34 3.1460.45b 1.0660.23 2.4660.49b
FENa % 1.6660.57 2.1960.48b 1.1960.26 1.1460.30 1.6660.40 2.3360.50a 1.2360.33 1.8060.46a
Data are means 6 SEM. Abreviations are: BP, blood pressure; GFR, glomerular filtration rate; RBF, renal blood flow; UV, urine flow rate; UNaV, absolute sodium
excretion; FENa, fractional excretion of sodium.
aP , 0.05, bP , 0.01, cP , 0.001, captopril vs. basal in each group
Response of the unilateral ureteral obstruction group Response of the unilateral ureteral obstruction group
treated with bosentanCaptopril infusion reduced RAP by 9 6 2% (P ,
0.001) but did not change RBF or GFR (Table 1). UV Captopril infusion reduced RAP by 6 6 2% (P ,
0.05). This response was similar to that recorded in thedecreased by 28 6 6% (P , 0.001), but UNaV and FENa
were unchanged during captopril infusion. Compared UUO group. Captopril elevated RBF by 35 6 10% (P ,
0.01) and GFR by 57 6 10% (P , 0.001). The responseswith the sham group, the changes in RAP and RBF were
similar in the two groups. However, changes in GFR of the RBF and GFR were similar to those observed in
the B/sham group. Comparing the B/UUO with the UUOwere different (26 6 14% vs. 34 6 9%, P , 0.05). UV,
UNaV, and FENa responses to captopril were also different group, the change in RBF was similar in the two groups.
However, the change in GFR was different (57 6 10%when compared with the sham group (228 6 6% vs. 60 6
20%, P , 0.001; 218 6 10% vs. 236 6 86%, P , 0.01; vs. 26 6 14%, P , 0.01). Captopril also increased UV,
UNaV, and FENa by 64 6 32% (P , 0.05), 185 6 62%and 21 6 15% vs. 169 6 79%, P , 0.05), respectively.
During Ang II infusion, RAP was maintained at prein- (P , 0.01), and 67 6 27% (P , 0.05). These changes
were similar to those observed in the B/sham group butfusion level by adjusting the aortic constrictor. Ang II
infusion did not change RBF; however, GFR, UV, UNaV, different from those in the UUO group: UV 64 6 32%
vs. 228 6 6% (P , 0.05); UNaV 185 6 62% vs. 218 6 10%and FENa increased by 106 6 40% (P , 0.01), 75 6 21%
(P , 0.001), 190 6 60% (P , 0.001), and 40 6 13% (P , 0.01); and FENa 67 6 27% vs. 21 6 15% (P , 0.05).
During Ang II infusion, RAP was successfully main-(P , 0.05), respectively. These renal function responses
to Ang II in the UUO group were different from those tained at a preinfusion level. Ang II reduced RBF and
GFR by 46 6 9% (P , 0.01) and 36 6 8% (P , 0.001),obtained in the sham group: RBF 26 6 12% vs. 242 6
9% (P , 0.05); GFR 106 6 40% vs. 230 6 8% (P , respectively (Fig. 1). The percentages of changes were
not different from those observed in the B/sham group0.01); UV 75 6 21% vs. 244 6 9% (P , 0.001); UNaV
190 6 60% vs. 252 6 9% (P , 0.01) and FENa 40 6 but were different from the UUO group (246 6 9% vs.
26 6 12% (P , 0.05) and 236 6 8% vs. 106 6 40%13% vs. 233 6 9% (P , 0.01; Figs. 1 and 2).
(P , 0.01), respectively. Ang II also reduced UV, UNaV,
Response of the sham group treated with bosentan and FENa by 46 6 6% (P , 0.001), 51 6 6% (P , 0.001),
and 21 6 6% (P , 0.05), respectively (Fig. 2). TheseCaptopril infusion reduced RAP by 9 6 3% (P ,
responses were similar to the B/sham group but were0.01), whereas RBF and GFR were increased by 48 6
different from the UUO group (P , 0.001 in all cases):11% (P , 0.01) and 77 6 36% (P , 0.01), respectively
246 6 6% vs. 75 6 21%, 251 6 6% vs. 190 6 60%,(Table 1). Captopril also increased UV, UNaV, and FENa
and 221 6 6% vs. 40 6 13%, respectively.by 58 6 40% (P , 0.05), 203 6 77% (P , 0.01) and 76 6
In all four groups, upon discontinuation of Ang II, all45% (P , 0.05), respectively. All of these responses
variables returned to values comparable to those foundwere similar to those observed in the sham group.
during captopril infusion alone.During Ang II infusion, RAP was successfully main-
tained at pre-Ang II level. Ang II infusion decreased
Response of the unilateral ureteral obstruction/RBF by 45 6 8% (P , 0.01) and GFR by 28 6 8% (P ,
long-term group0.05; Fig. 1). Ang II reduced UV, UNaV, and FENa by 43 6
4% (P , 0.001), 53 6 4% (P , 0.001), and 31 6 7% The blood pressure and renal function data from the
UUO/LT group throughout the experimental protocol(P , 0.05), respectively (Fig. 2). These responses were
similar to those observed in the sham group. are given in Table 2. In this group, the baseline RAP
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Fig. 1. The percentage change of renal blood flow (RBF) (A) and
glomerular filtration rate (B) to Ang II infusion. Values represent mean 6
SEM. Symbols are: (h) Sham group; (j) UUO group; ( ) B/sham
group; ( ) B/UUO group; *P , 0.05; **P , 0.01; ***P , 0.001.
was higher than the other groups. Comparing it with the
UUO group, for example, the blood pressure was 6%
higher (P , 0.05).
Under baseline conditions, RBF, GFR, UV, UNaV, Fig. 2. The percentage of (A) urine flow rate (UV), (B) absolute so-
dium excretion (UNaV), and (C ) fractional excretion of sodium (FENa)and FENa in the left, previously obstructed kidney were
to Ang II infusion. Values represent mean 6 SEM. Symbols are: (h)similar to the right control kidney. sham group; (j) UUO group; ( ) B/sham group; ( ) B/UUO group;
Captopril decreased RAP by 7 6 1% (P , 0.01). In *P , 0.05; **P , 0.01; ***P , 0.001.
the right control kidney, captopril increased RBF and
GFR by 43 6 12% (P , 0.05) and 33 6 7% (P , 0.01),
respectively. Captopril also increased UV, UNaV, and (P , 0.001), respectively. In addition, UV, UNaV, and
FENa by 30 6 4%, 150 6 32%, and 82 6 21% (P , FENa decreased by 59 6 6% (P , 0.001), 69 6 5% (P ,
0.001 in all the cases), respectively. In the left, previously 0.001), and 35 6 8% (P , 0.05), respectively. In the left
obstructed, kidney, RBF and GFR rose during captopril kidney, Ang II also reduced RBF and GFR by 47 6 8%
infusion by 45 6 12% and 32 6 6%, respectively (P , and 38 6 6%, respectively (P , 0.01 in both cases). With
0.01 in both cases). During this time, UV, UNaV, and regard to the tubular parameters, UV, UNaV, and FENa
FENa also increased by 43 6 14% (P , 0.01), 194 6 83% decreased by 53 6 7% (P , 0.001), 64 6 5% (P ,
(P , 0.001), and 111 6 59% (P , 0.01), respectively. 0.001), and 42 6 8% (P , 0.05), respectively. All of
These changes were similar in the two kidneys. these responses were similar in the two kidneys. In both
As in the other groups, RAP was maintained during kidneys, during the recovery period, all of the variables
Ang II infusion. In the right kidney, Ang II decreased returned to values comparable to those found with capto-
pril alone.RBF and GFR by 57 6 9% (P , 0.01) and 49 6 8%
Hammad et al: Ureteral obstruction and ETs 247
Table 2. Blood pressure and renal hemodynamic and tubular data of UUO/LT group (N 5 9)
Basal Captopril Angiotensin II Recovery
BP mm Hg 10761 9961b 9862 10162
RBF mL/min/g (R) 3.0560.36 4.5760.82a 1.8460.42f 3.0660.61
(L) 3.3660.25 4.8960.54b 2.3860.25f 3.1560.43
GFR mL/min/g (R) 0.5660.06 0.7460.09b 0.4160.09f 0.6360.11
(L) 0.6260.06 0.8360.09b 0.4860.04f 0.6060.08
UV lL/min/g (R) 7.7460.73 10.0260.87c 4.3660.93g 9.9661.86
(L) 9.4361.05 12.8861.36b 6.6461.63g 12.2062.20
UNaV lmol/min/g (R) 0.7360.11 1.5760.16c 0.5260.11g 1.7560.39
(L) 1.0360.22 2.0860.33c 0.8560.21g 2.1260.50
FENa % (R) 1.1860.32 1.7860.37c 1.2260.27e 2.3360.54
(L) 1.4060.37 1.9960.42b 1.1960.27e 2.6060.55
Data are means 6 SEM. Abreviations are: BP, blood pressure; GFR, glomerular filtration rate; RBF, renal blood flow; UV, urine flow rate; UNaV, absolute sodium
excretion; FENa, fractional excretion of sodium; R, right kidney; L, left kidney.
aP , 0.05, bP , 0.01, cP , 0.001, captopril vs. basal
eP , 0.05, fP , 0.01, gP , 0.001, angiotensin II vs. captopril
DISCUSSION In our study, the reversal of the obstruction was con-
firmed by microscopic observation of the passage ofUreteral obstruction is one form of obstructive uropa-
urine past the site of obstruction. Although it is possiblethy, a condition that includes any structural or functional
that minor edema and surgical adhesion, which occurchange in the urinary tract that impedes normal flow of
postoperatively, might have caused a partial obstruction.urine. In humans, ureteral obstruction is associated with
Such an obstruction would have had only a minor effectpain and renal damage [1, 2]. The extent of the damage
on the recovery from ureteral obstruction since baselineis related to the duration of the obstruction and to the
renal function returned to normal after 14 days, consis-degree of the blockade. Longer durations and complete
tent with the observations reported by Bander et al [4].blockade give rise to more severe damage [28, 29]. The
To test the integrity of the postobstructed kidney, ourrenal damage is associated with alterations in glomerular
protocol consisted of stimulating the kidney with a rela-filtration and tubular function, which may or may not
tively low physiological concentration of Ang II (25 ng/be reversible depending on the duration of the obstruc-
kg/min) [14, 32]. To more clearly resolve the effect oftion. The effects of ureteral obstruction on renal function
the Ang II infusion on renal function, we blocked thein the immediate period following relief of obstruction
endogenous production of Ang II using captopril priorare well studied. However, the long-term recovery from
to the exogenous Ang II infusion. The effectiveness ofureteral obstruction is less well understood [20].
this blockade was demonstrated by the reduction of theIn our study, we chose to use a period of 24 hours of
pressor response to Ang I to less than 10% of precapto-ureteral obstruction as a model of obstructive uropathy
pril pressor response [25, 32]. In addition, the renalbecause this duration was severe enough to cause a re-
nerves were sectioned to avoid any neural reflex alter-versible damage to the kidney. In this model, immedi-
ations in renal function. Furthermore, the renal arteryately following the creation of the obstruction, there is
pressure was servo-controlled to pre-Ang II infusion lev-an increase in RBF, which has been shown to be due to
els to avoid changes in renal perfusion pressure influenc-the release of vasodilatory prostaglandins [30]. Subse-
ing the renal response to Ang II.quently, over the next few hours, RBF progressively falls
In the sham group, captopril administration caused auntil it reaches 50% of control values at 24 hours. Over
prompt fall in RAP and an increase in both RBF andthe same time period, GFR falls to around 25% of con-
GFR (Table 1), which is consistent with previous reportstrol values [31]. Following reversal of the obstruction,
[33–35]. The increase in RBF in this study was compara-RBF and GFR gradually increase over the next 14 days
ble to that reported by Mattson and Roman [33–35], butto values similar to those recorded in control kidneys
their increase in GFR was twice that in our study. This[4]. Immediately after reversal, there is an increase in
difference is probably explained by the relative hypovo-sodium and water excretion [4, 29], which decreases to
lemic state of their animals compared with those in thenormal over 14 days [4]. Histologically, there is a de-
present study, and hypovolemia is known to elevate basalcrease in the number of functioning nephrons, suggesting
plasma renin activity.an increase in single-nephron GFR [4]. It has also been
To isolate the intrarenal action of Ang II from renalnoted that the osmolality of the urine remains lower
effects associated with increases in RAP, the aorta,than normal even after 60 days postobstruction, sug-
above the level of the kidneys, was constricted to main-gesting that there is a persistent functional defect in the
distal nephron [4]. tain RAP at preinfusion levels. During this infusion pe-
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riod, RBF and GFR decreased, as did the urine flow resulted in an antinatriuresis and antidiuresis. This is
consistent with the observations of Barraclough, Jones,rate and UNaV and FENa (Figs. 1 and 2). These responses
to a low dose of Ang II were similar to those reported and Marsden [36] and Ding et al [41] in normotensive
rats. In the UUO animals, captopril caused a decreaseby others [33, 36]. The decrease in urine flow rate and
UNaV and FENa suggests that Ang II increased proximal in water excretion, with no measurable change in sodium
handling. Conversely, Ang II resulted in a natriuresistubular sodium and water reabsorption.
The baseline hemodynamic and tubular parameters in and diuresis. Much of this response is caused by the
increase in GFR and the increased filtered load. How-the UUO group were similar to those in the sham group
and were consistent with the observations of Bander et ever, the fact that there was an increase in FENa suggests
that there was also a decrease in tubular reabsorptional [4]. In the UUO group, captopril caused a fall in RAP
(Table 1) similar to that observed in the sham group. In in response to Ang II. One possible mechanism for this
is that the large increase in GFR results in an increasedcontrast to the sham group, however, captopril did not
increase RBF or GFR in the UUO group. Further, when delivery of Ang II to the luminal Ang II receptors. Stimu-
lation of these receptors has been shown to give rise toAng II was infused into the UUO rats, RBF did not
change, but a significant increase in GFR occurred. This a natriuresis and diuresis [42].
In the kidney, ET receptors are located in the afferentsuggests that Ang II does not contribute appreciably to
renal vascular tone in these postobstructed kidneys. One and efferent arterioles [43, 44] on the mesangial cells
within the glomerulus [45] and on the tubules [44]. Thepossible explanation for these findings is that the renin-
angiotensin system is not active in these postobstructed primary action of ET appears to be vasoconstriction re-
sulting in a decrease in RBF [46]. Plasma and tissuekidneys. This, however, seems unlikely given the fall in
RAP observed in response to captopril, which indicated levels of ET are elevated in a number of renal pathophys-
iological disorders such as hypertension, renal failure,an active renin-angiotensin system. Alternatively, down-
regulation of Ang II type 1 receptors (AT1), the main renal ischemia [7, 47], and UUO [8].
Endothelin has been implicated in the tissue damagereceptors found in the preglomerular vessels [37], may
have occurred in response to UUO. Indeed, Pimentel, and dysfunction associated with UUO. Indeed, ET
blockade using specific anti-ET antibodies attenuatedWang, and Martinez-Maldonado have reported that 24
hours following UUO, there was a down-regulation of the fall in renal plasma flow and GFR in rats subjected
to unilateral reversal of 24-hour bilateral ureteral ob-the AT1 receptor mRNA expression mediated by the
increase in intrarenal Ang II levels [38]. In addition, struction [9]. ET synthesis and release are augmented
by circulating and intrarenal Ang II [22, 48, 49]. TheBander et al observed that RBF returned to baseline
only 14 days after the reversal of the obstruction [4]. subsequent increase in circulating ET probably results
in intense and prolonged constriction of the efferentThus, it would appear that the AT1 receptors remain
down-regulated for at least 14 days. In the current study, arterioles in particular [50], which would serve to main-
tain some level of filtration.Ang II infusion caused no vasoconstriction of the affer-
ent arterioles and vasoconstriction of the efferent arteri- To establish whether blockade of ET receptors had
any direct influence on renal function, we treated a groupoles, which led to elevation of glomerular hydrostatic
pressure and GFR, indicating that only Ang II receptors of sham UUO rats with bosentan. As shown in Table 1,
blockade of the ET receptors had no measurable effecton the afferent arterioles remained responsive. Indeed,
it has been suggested that AT1 receptors on the efferent on the baseline renal function or on the response to
captopril. Similarly, no effect on the response to Ang IIarterioles are more sensitive to Ang II than those on the
afferent arterioles [14, 39, 40]. It is possible that UUO was observed (Figs. 1 and 2). These results suggest that
under normal conditions, ET blockade does not haveexaggerates the differential sensitivity of these receptors.
Furthermore, a selective down-regulation of the AT1 any long-lasting effect on the control of renal function.
Following treatment with bosentan, renal responsesreceptors has been reported in various physiological con-
ditions. Amiri and Garcia observed that activation of to captopril and Ang II in the UUO animals were similar
to those observed in the sham and the B/sham animals.the renin-angiotensin system using a low-sodium diet
resulted in a down-regulation of Ang II receptors in Clearly, blockade of the ET receptors prevents the renal
dysfunction associated with UUO.preglomerular vessels, whereas the glomerular AT1 re-
ceptors were not changed [37]. This lack of Ang II re- It has been demonstrated that UUO increases both
Ang II [1, 15–17] and ET [8], bringing about the renalsponsiveness in the afferent arteriole may be physiologi-
cally relevant in that RBF would be better maintained hemodynamic changes described previously in this arti-
cle. The interrelationship between Ang II and ET is suchin the postobstruction period.
Angiotensin II plays an important role in the tubular that each one potentiates the production of the other.
This could explain the elevated concentrations of bothhandling of sodium and water. Captopril treatment in
the sham rats resulted in an increase in sodium and water vasoactive factors even after the UUO has been re-
versed. In addition, the proinflammatory nature of ETexcretion, whereas administration of exogenous Ang II
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